Oppenheimer Reiterates Outperform on Biogen, Maintains $295 Price Target

Biogen Inc. +0.23%

Biogen Inc.

BIIB

230.57

+0.23%

Oppenheimer analyst Jay Olson reiterates Biogen (NASDAQ: BIIB) with a Outperform and maintains $295 price target.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via